• Fri. Jan 22nd, 2021

Compounding Chemotherapy Market Research Report—Forecast till 2027

BySaurabh Sinha

Jan 13, 2021

Market Highlights

Global Compounding Chemotherapy Market is expected to have a market value of USD 635.58 Million by 2027.

Compounding is the science of combining and developing drugs that are unique to the needs of the patients. These medications are made depending on the recommendation of the doctor in which the individual constituents are mixed in accordance with the prescribed dose. The trained pharmacists are permitted to modify the prescription for the patient meeting their individual needs, including flavors, dosage formulations, strengths, and absence of constituents for which the patient is susceptible or allergic.

FOR MORE DETAILS : https://medium.com/healthandhealthcareresearchreports/global-compounding-chemotherapy-market-to-paramount-a-market-top-key-competitors-analysis-upto-2023-6a8b2efb5894

Segment Analysis

The Global Compounding Chemotherapy Market, based on dose, has been segmented into chemotherapeutic and non-chemotherapeutics. The global compounding chemotherapy market, by compounding type, has been segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The global compounding chemotherapy market, by delivery method, has been segmented into gravimetric automated compounding device (weight-based) and volumetric automated compounding device (volume-based). The global compounding chemotherapy market, by sterility, has been segmented into sterile and non-sterile. On the basis of technology, the market has been segmented into with robotic arms and without robotic arms. The market for the global compounding chemotherapy, by robotic arms, is bifurcated into robots for compounding of intravenous cytotoxic doses and non-cytotoxic dose. The global compounding chemotherapy market, by compounder type, has been segmented into Pharmoduct, equashield pro, medimix, integra, and others.

Regional Analysis

Global Compounding Chemotherapy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The rapid development of alternative therapies, such as oncological chemotherapy, has been reported to offer better treatment alternatives for breast, lung, and prostate cancer. The field of precise and personal medicine (PPM) is expanding to deliver therapies focused on current or previous physical fitness and environmental skills in a patient or community.

The European compounding chemotherapy market has been further segmented into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The increased use of chemotherapy and custom medications and the growing need for mitigating prescription errors are the main drivers of the market. Furthermore, high cost, reluctance to implement the compounding process, and COVID-19 pandemic are likely to have a significant effect on market growth.

ALSO READ : https://healthcareworldtoday.wordpress.com/2021/01/10/global-compounding-chemotherapy-market-to-paramount-a-market-top-key-competitors-analysis-upto-2023/

The compounding chemotherapy market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to register the highest growth rate during the forecast period. This rapid growth is mainly due to the rise in R&D financing for the healthcare sector by developing countries such as China and India. Various other factors driving consumer development include an increased prevalence of cancer, aging, rising demand for new treatments and patent expiry of leading medications, regulatory efforts, as well as an increased general understanding of various forms of cancer and possible treatment choices.

The Middle East & Africa compounding chemotherapy market is segmented into the Middle East and Africa. The market for compounding chemotherapy is growing at a significant rate in the Middle East & Africa due to the increasing number of companies and subsidiaries in the region offering treatment options. Comecer S.p.A, an Italian biotechnology company, generates approximately 55% of its annual sales through its specialized radiation shielding systems used by customers in the production, handling, and dispensing of radiopharmaceutical drugs. The company has a presence in Algeria, the Democratic Republic of the Congo, Libya, Madagascar, Morocco, Egypt, Nigeria, South Africa, Tunisia, Uganda, and other African countries.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Compounding Chemotherapy Market — B. Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.

https://tokentimes.io/